id	等位基因	注释文本
885	*17	The CYP2C1917 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C1917 allele in combination with a normal or increased function allele may have increased metabolism of pantoprazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of pantoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.
884	*3	The CYP2C193 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C193 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of pantoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.
883	*2	The CYP2C192 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C192 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of pantoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.
882	*1	The CYP2C191 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C191 allele in combination with another normal function allele may have increased metabolism of pantoprazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of pantoprazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.

id	证据的ID	总结
3725	1450808617	CYP2C19 2/2 + 2/3 + 3/3 are associated with decreased metabolism of pantoprazole in healthy individuals as compared to CYP2C19 1/1 + 1/2 + 1/3.
3724	1447947333	CYP2C19 2/2 is associated with decreased clearance of pantoprazole in healthy individuals as compared to CYP2C19 1/1.
3723	1447947325	CYP2C19 1/2 is associated with decreased clearance of pantoprazole in healthy individuals as compared to CYP2C19 1/1.
3722	1447947314	CYP2C19 17 is associated with increased clearance of pantoprazole in healthy individuals as compared to CYP2C19 1.
3721	1447947227	CYP2C19 1/1 + 1/17 is associated with increased metabolism of pantoprazole in children as compared to CYP2C19 1/2 + 2/17.
3720	982047471	CYP2C19 2/2 is associated with decreased clearance of pantoprazole in children as compared to CYP2C19 1/1.
3719	827789167	CYP2C19 1/2 is associated with decreased metabolism of pantoprazole in healthy individuals as compared to CYP2C19 1/1.
3718	1450807240	CYP2C19 poor metabolizers are associated with decreased metabolism of lansoprazole, omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 normal metabolizers.
3717	1450807008	Genotypes 2/2 + 2/3 + 3/3 are associated with decreased metabolism of pantoprazole in healthy individuals as compared to genotypes 1/1 + 1/2 + 1/3.
3716	PA166104958	Annotation of DPWG Guideline for pantoprazole and CYP2C19
3715	PA166219103	Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19

id	类型	评论
1312	Update	Added DPWG guideline.
1311	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1310	Update	Changed LOE to 1A due to CPIC PPI guideline
1309	Update	Updated 'extensive metabolizer' term to 'normal metabolizer' following CPIC Term Standardization Project.
1308	Update	Updated OMB race to appropriate biogeographical group

最新招商产品更多>>